The abstract is read at the publisher; the summary is JClub's.
Historical or contemporary smallpox vaccination is linked to limited neutralising activity across MPXV clades Ia, Ib, and IIb, with PRNT50 responder frequencies as low as 3–15% after MVA-BN alone.
- Why it matters: The 2022 MPXV clade IIb outbreak and subsequent MVA-BN vaccination raised questions about how well existing humoral immunity covers newly expanding clade Ib. This study addresses constraints on cross-clade antibody-mediated protection.
- What they did: Plasma from 191 participants (232 samples) at sites in the USA, Brazil, and Portugal was tested for ELISA binding and PRNT50 neutralisation against MPXV clades Ia, Ib, and IIb, using control thresholds from uninfected, unvaccinated individuals.
- The result: After MPXV clade IIb infection, antibody binding was broad but neutralisation of clade Ib was low (median log10 PRNT50 1·00 [1·00–1·00]), and A35-targeted binding was less efficient for clade I A35 variants than clade IIb.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.